These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 28772286)

  • 1. Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort.
    Mai PL; Khincha PP; Loud JT; DeCastro RM; Bremer RC; Peters JA; Liu CY; Bluemke DA; Malayeri AA; Savage SA
    JAMA Oncol; 2017 Dec; 3(12):1640-1645. PubMed ID: 28772286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
    Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC
    Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
    Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
    Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
    Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
    Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
    de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA
    Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
    Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
    J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The benefit and burden of cancer screening in Li-Fraumeni syndrome: a case report.
    Jhaveri AP; Bale A; Lovick N; Zuckerman K; Deshpande H; Rath K; Schwartz P; Hofstatter EW
    Yale J Biol Med; 2015 Jun; 88(2):181-5. PubMed ID: 26029016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.
    Villani A; Tabori U; Schiffman J; Shlien A; Beyene J; Druker H; Novokmet A; Finlay J; Malkin D
    Lancet Oncol; 2011 Jun; 12(6):559-67. PubMed ID: 21601526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.
    Ballinger ML; Best A; Mai PL; Khincha PP; Loud JT; Peters JA; Achatz MI; Chojniak R; Balieiro da Costa A; Santiago KM; Garber J; O'Neill AF; Eeles RA; Evans DG; Bleiker E; Sonke GS; Ruijs M; Loo C; Schiffman J; Naumer A; Kohlmann W; Strong LC; Bojadzieva J; Malkin D; Rednam SP; Stoffel EM; Koeppe E; Weitzel JN; Slavin TP; Nehoray B; Robson M; Walsh M; Manelli L; Villani A; Thomas DM; Savage SA
    JAMA Oncol; 2017 Dec; 3(12):1634-1639. PubMed ID: 28772291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic
    Bancroft EK; Saya S; Brown E; Thomas S; Taylor N; Rothwell J; Pope J; Chamberlain A; Page E; Benafif S; Hanson H; Dias A; Mikropoulos C; Izatt L; Side L; Walker L; Donaldson A; Cook JA; Barwell J; Wiles V; Limb L; Eccles DM; Leach MO; Shanley S; Gilbert FJ; Gallagher D; Rajashanker B; Whitehouse RW; Koh DM; Sohaib SA; Evans DG; Eeles RA; Walker LG
    J Med Genet; 2020 Apr; 57(4):226-236. PubMed ID: 31719169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
    Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
    Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
    Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
    JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
    Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
    JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-body magnetic resonance imaging of Li-Fraumeni syndrome patients: observations from a two rounds screening of Brazilian patients.
    Paixão D; Guimarães MD; de Andrade KC; Nóbrega AF; Chojniak R; Achatz MI
    Cancer Imaging; 2018 Aug; 18(1):27. PubMed ID: 30107858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome.
    Masciari S; Van den Abbeele AD; Diller LR; Rastarhuyeva I; Yap J; Schneider K; Digianni L; Li FP; Fraumeni JF; Syngal S; Garber JE
    JAMA; 2008 Mar; 299(11):1315-9. PubMed ID: 18349092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric cancer in individuals with Li-Fraumeni syndrome.
    Masciari S; Dewanwala A; Stoffel EM; Lauwers GY; Zheng H; Achatz MI; Riegert-Johnson D; Foretova L; Silva EM; Digianni L; Verselis SJ; Schneider K; Li FP; Fraumeni J; Garber JE; Syngal S
    Genet Med; 2011 Jul; 13(7):651-7. PubMed ID: 21552135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls.
    Saya S; Killick E; Thomas S; Taylor N; Bancroft EK; Rothwell J; Benafif S; Dias A; Mikropoulos C; Pope J; Chamberlain A; Gunapala R; ; Izatt L; Side L; Walker L; Tomkins S; Cook J; Barwell J; Wiles V; Limb L; Eccles D; Leach MO; Shanley S; Gilbert FJ; Hanson H; Gallagher D; Rajashanker B; Whitehouse RW; Koh DM; Sohaib SA; Evans DG; Eeles RA
    Fam Cancer; 2017 Jul; 16(3):433-440. PubMed ID: 28091804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of interim blood tests for cancer screening in Li-Fraumeni syndrome.
    Oba L; Best AF; Mai PL; Achatz MI; Albert PS; Savage SA; Khincha PP
    Fam Cancer; 2022 Jul; 21(3):333-336. PubMed ID: 34076823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.